反応式
OC1C=CC(C[NH:7]C(=O)C2C=CC(NC3C4N(C=CN=4)C(C4C=NNC=4)=CN=3)=CC=2)=CC=1.[Br:33][C:34]1[N:39]2[CH:40]=[CH:41][N:42]=[C:38]2[C:37](Br)=[N:36][CH:35]=1.[CH2:44]([N:46]([CH2:59][CH3:60])[CH2:47][CH2:48][NH:49][C:50]([C:52]1[CH:57]=[CH:56][C:55]([NH2:58])=[CH:54][N:53]=1)=[O:51])[CH3:45].CC([O-])(C)C.[Na+]>C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].CC1(C)C2C(=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=CC=2)OC2C(P(C3C=CC=CC=3)C3C=CC=CC=3)=CC=CC1=2.C1(C)C=CC=CC=1>[NH3:7].[CH2:59]([N:46]([CH2:44][CH3:45])[CH2:47][CH2:48][NH:49][C:50]([C:52]1[CH:57]=[CH:56][C:55]([NH:58][C:37]2[C:38]3[N:39]([CH:40]=[CH:41][N:42]=3)[C:34]([Br:33])=[CH:35][N:36]=2)=[CH:54][N:53]=1)=[O:51])[CH3:60]参加物
9
反応物 4
生成物 2
試薬・触媒・溶媒 3
実験手順
In the same way as described for Compound 90, step 1, using 5,8-dibromoimidazo[1,2-a]pyrazine (0.272 g, 0.982 mmol), 5-amino-pyridine-2-carboxylic acid (2-diethylamino-ethyl)-amide (0.197 g, 0.835 mmol), NaOtBu (0.132 g, 1.37 mmol), Pd2(dba)3 (18 mg, 0.02 mmol), Xantphos (22 mg, 0.038 mmol) and toluene (3 mL). The crude material is purified by silica gel column chromatography eluting with DCM followed by 94:6 DCM:NH3 (7M in MeOH) to afford the title compound (0.263 g, 72%). HPLC (254 nm) Rt 2.09 min (72%).
後処理
- customThe crude material is purified by silica gel column chromatography
- washeluting with DCM
出典と根拠
- ORDレコード
- ord-645031713f7447d1b96085545a24359c
- 出典データセット
- uspto-grants-2011_02
- 特許番号
- US07893058B2
関連ノート
読み込み中…